Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR 238.75
-3.45 (-1.42%)
At close: Jul 27, 2026
Medicamen Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 96.41 | 71.08 | 109.31 | 148.44 | 148.98 |
Depreciation & Amortization | 72.19 | 69.1 | 69.19 | 62.56 | 56.72 |
Other Amortization | - | 1.56 | 1.74 | 1.1 | 0.99 |
Loss (Gain) From Sale of Assets | - | - | 0 | -0.07 | -0.01 |
Other Operating Activities | 21.01 | 39.15 | 27.53 | 12.8 | 12.62 |
Change in Accounts Receivable | -129.28 | -136.4 | 99.99 | -20.35 | -106.76 |
Change in Inventory | -79.42 | -27.62 | -143.18 | -180.48 | -218.06 |
Change in Accounts Payable | -26.45 | 37.03 | -86.37 | 42.86 | 110.89 |
Change in Other Net Operating Assets | -286.18 | -135.48 | -145.65 | -129.8 | 35.73 |
Operating Cash Flow | -331.72 | -81.59 | -67.44 | -62.93 | 41.09 |
Operating Cash Flow Growth | - | - | - | - | -67.83% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -47.78 | -21.89 | -62.87 | -66.01 | -86.08 |
Other Investing Activities | 17.39 | 7.92 | 7.24 | 7.21 | 1.35 |
Investing Cash Flow | -30.39 | -13.97 | -55.63 | -58.8 | -84.73 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | 121.12 | - | 62.49 | 40.38 | 83.46 |
Long-Term Debt Issued | 24.18 | 24.79 | 3.86 | - | - |
Total Debt Issued | 145.31 | 24.79 | 66.35 | 40.38 | 83.46 |
Short-Term Debt Repaid | - | -0.43 | - | - | - |
Long-Term Debt Repaid | - | - | - | -42.04 | -13.31 |
Total Debt Repaid | - | -0.43 | - | -42.04 | -13.31 |
Net Debt Issued (Repaid) | 145.31 | 24.36 | 66.35 | -1.66 | 70.15 |
Issuance of Common Stock | 449.55 | 5.21 | 53.41 | 334.12 | - |
Common Dividends Paid | -13.56 | -12.72 | -12.65 | -12.65 | -12.22 |
Other Financing Activities | 55.86 | -31.56 | -43.97 | -28.53 | -14.96 |
Financing Cash Flow | 637.16 | -14.71 | 63.14 | 291.27 | 42.98 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | - | -0 | - |
Net Cash Flow | 275.05 | -110.26 | -59.93 | 169.54 | -0.66 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -379.5 | -103.47 | -130.31 | -128.94 | -44.99 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -18.89% | -6.18% | -7.27% | -9.15% | -3.90% |
Free Cash Flow Per Share | -27.98 | -8.14 | -10.29 | -10.19 | -3.68 |
Levered Free Cash Flow | -235.82 | -122.84 | 23.34 | -86.46 | -84.89 |
Unlevered Free Cash Flow | -213.96 | -103.12 | 50.83 | -68.2 | -76.13 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 34.97 | 31.56 | 43.97 | 29.23 | 14.01 |
Cash Income Tax Paid | 20 | 13.5 | 30.65 | 26.2 | 32 |
Change in Working Capital | -521.34 | -262.48 | -275.21 | -287.76 | -178.21 |